Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 19 April 2017

Karolinska Development Annual Report 2016 published

Karolinska Development AB (publ)    

Published: 19:00 CEST 19-04-2017 /GlobeNewswire /Source: Karolinska Development AB (publ) / : KDEV /ISIN: SE0002190926

Karolinska Development Annual Report 2016 published

STOCKHOLM - 19 April 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2016.

 

The report is now available to download at www.karolinskadevelopment.com

 

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com
 

Christian Tange, CFO, Karolinska Development AB
Phone:
+46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

 

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

 

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Jim Van heusden, on April 19, 2017 at 07:00 pm (CEST).



Karolinska Development Annual Report 2016 English



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Karolinska Development AB (publ), Tomtebodavägen 23 A, Solna SE-17165, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.